MedTrace Logo

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

NCT01631331 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-12-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.

Conditions

  • Basal Cell Carcinoma of the Skin
  • Recurrent Skin Cancer

Interventions

DRUG

vismodegib

Given PO

PROCEDURE

Mohs surgery

Undergo Mohs surgery

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University Hospitals Cleveland Medical Center

    collaborator OTHER

  • Stanford University

    lead OTHER

Principal Investigators

  • Jean Tang · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2015-09-17
Completion
2016-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01631331 on ClinicalTrials.gov